^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    epitinib (HMPL-813)

    i
    Other names: HMPL-813
    Company:
    Hutchmed
    Drug class:
    EGFR inhibitor
    Related drugs:
    almost2years
    Safety and Efficacy of Epitinib for EGFR-Mutant Non-Small Cell Lung Cancer With Brain Metastases: Open-Label Multicentre Dose-Expansion Phase Ib Study. (PubMed, Clin Lung Cancer)
    In patients with EGFR-mutant NSCLC with brain metastasis, epitinib was well tolerable with a promising efficacy. According to the comprehensive assessment on safety and efficacy, 160 mg QD could be the recommended phase 2 dose.
    P1 data • Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation
    |
    epitinib (HMPL-813)
    4years
    HMPL-813 in Treating Patients With Glioblastoma (clinicaltrials.gov)
    P1, N=29, Recruiting, Hutchison Medipharma Limited | Trial primary completion date: Dec 2019 --> Jun 2020
    Clinical • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR amplification
    |
    epitinib (HMPL-813)